Entera Bio Ltd.(ENTX)Earnings, Financials & Key Ratios

"Entera Bio faces a precarious outlook as its reliance on non-recurring research collaborations has resulted in effectively zero revenue, leaving the company entirely dependent on external capital to fund its $2.2 million quarterly R&D burn. The firm's inability to demonstrate operating leverage, combined with a significant accumulation of $128.9 million in retained losses, suggests that future clinical development will likely necessitate further dilutive financing. Investors should monitor the rapid depletion of the cash buffer, which has fallen from $12.6 million in 2025Q1 to $4.1 million as of 2026Q1, as the primary risk to long-term viability."